<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Make</title>
	<atom:link href="http://www.tapanray.in/tag/make/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Does ‘Free-Market Economy’ Work For Branded Generic Drugs In India?</title>
		<link>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-free-market-economy-work-for-branded-generic-drugs-in-india</link>
		<comments>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/#comments</comments>
		<pubDate>Mon, 27 Apr 2015 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Badm Medicine]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[chemicals. and. fertilizers]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[Delhi School of Economics]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DSE]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Editorial]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Free Market Economy]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[IJME]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradox]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[‘Dorfman-Steiner’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6557</guid>
		<description><![CDATA[On April 20, 2015, a panel of 31 lawmakers of the Standing Committee on Chemicals and Fertilizers tabled its report in the Indian Parliament. The committee emphasized that patients in India should have access to all medicines, including life saving drugs, &#8230; <a href="http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-free-market-economy-work-for-branded-generic-drugs-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India…Sell Anywhere in The World”: An Indian Pharma Perspective</title>
		<link>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective</link>
		<comments>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/#comments</comments>
		<pubDate>Mon, 29 Sep 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[alert]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Bureau]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global. world]]></category>
		<category><![CDATA[Harvard]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[independence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[letters]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[production]]></category>
		<category><![CDATA[ramparts. red fort]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sell]]></category>
		<category><![CDATA[speech]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[warning]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6039</guid>
		<description><![CDATA[In his Independent Day speech from the ramparts of the Red Fort on August 15, 2014, Indian Prime Minister Modi gave a clarion call to all investors of the world, “Come, make in India”, “Come, manufacture in India”, “Sell in &#8230; <a href="http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-indiasell-anywhere-in-the-world-an-indian-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India-like New Broader Compulsory Licensing Provisions in China Could Make the Global Pharma Players Edgy</title>
		<link>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy</link>
		<comments>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/#comments</comments>
		<pubDate>Mon, 18 Jun 2012 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[Edgy]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Provisions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=79</guid>
		<description><![CDATA[Quite close on the heel of grant of Compulsory License (CL) to Bayer AG’s expensive Kidney and Liver cancer drug Sorafenib to the domestic Indian manufacturer Natco by the Indian Patent Office, as provided in the Indian Patent Law, China &#8230; <a href="http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tackling the menace of counterfeit medicines – vested interests or petty sentiments should not make the pressing public healthcare issue irrelevant.</title>
		<link>http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant</link>
		<comments>http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/#comments</comments>
		<pubDate>Mon, 29 Jun 2009 00:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[interests]]></category>
		<category><![CDATA[irrelevant. pharmaceuticals]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[or]]></category>
		<category><![CDATA[petty]]></category>
		<category><![CDATA[pressing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiments]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tackling]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[vested]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=848</guid>
		<description><![CDATA[There are following three clearly emerging views on the global issue of counterfeit drugs:1. The innovator companies feel that the generic pharmaceutical industry and the drug regulators are not really very keen to effectively address and resolve this global public &#8230; <a href="http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/tackling-the-menace-of-counterfeit-medicines-vested-interests-or-petty-sentiments-should-not-make-the-pressing-public-healthcare-issue-irrelevant/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
